CTMX PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d ⚠ clustered

CTMX ▼ -45.32% at T+60d

SHORT call ✓ call won +45.32% · α vs SPY +55.18% · entry $5.45 → $2.98

Currently $3.01 · +44.77% from $5.45 entry (call sign-flipped)

Entry anchored
Mar 16, 04:01 PM ET
via Databento tick

T+1d

-19.27%

call +19.27% · α +17.87%

$4.40

settled 3mo ago

T+5d

-22.20%

call +22.20% · α +19.55%

$4.24

settled 3mo ago

T+20d

-16.33%

call +16.33% · α +20.63%

$4.56

settled 2mo ago

T+60d

-45.32%

call +45.32% · α +55.18%

$2.98

settled 3d ago

Price Chart

Loading chart...

Executive Summary

CytomX Therapeutics announced a public offering of $250.0 million in common stock and pre-funded warrants, with an additional $37.5 million option for underwriters to purchase more shares. The offering is expected to dilute existing shareholders and is subject to market conditions.

Key Financial Metrics

Deal Value

$250.0M

Actionable Insight

Traders should anticipate near-term downward pressure on CTMX shares due to dilution concerns; monitor for pricing and final size of the offering. Consider hedging or reducing positions ahead of pricing.

Key Facts

CytomX announced a public offering of $250.0 million in common stock and pre-funded warrants.
Underwriters have a 30-day option to purchase up to an additional $37.5 million in shares.
All securities are being offered directly by CytomX, indicating primary issuance and not a secondary sale.
Proceeds will likely be used for general corporate purposes, R&D, or clinical trial funding, though specific use was not detailed in the release.
The offering represents significant dilution to existing shareholders, especially if the full $287.5 million is raised.

Financial Impact

$250.0 million raised, potentially $287.5 million with overallotment; significant dilution expected

dilutioncashequity

Risk Factors

Dilution from new share issuance could negatively impact stock price.
Market conditions may delay or reduce the size of the offering, creating uncertainty.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3256708

4 reports for CTMX

T+1T+5T+20T+60

Filters

Reports for CTMX — sortable, filterable
	Type				Now
Mar 18, 2026 12w ago	Press Release NEUTRAL ★ 6/10	$4.40 $2.98	▼ −32.27%	▼ −43.80%	$3.01 (−31.59%)
Mar 16, 2026 12w ago	Press Release BEARISH ★ 7/10	$5.45 $2.98	▲ +45.32%	▲ +55.18%	$3.01 (+44.77%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$6.75 $2.94	▼ −56.44%	▼ −66.93%	$3.01 (−55.41%)
Mar 4, 2026 14w ago	Press Release NEUTRAL ★ 3/10	$5.07 $3.71	▼ −26.82%	▼ −36.91%	$3.01 (−40.63%)

US Market Status

Market Closed — Opens Mon (49h 33m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access